Manuka Honey in Preventing Esophagitis-Related Pain in Patients Receiving Chemotherapy and Radiation Therapy For Lung Cancer
RATIONALE: Manuka honey may prevent or reduce esophagitis-related pain caused by chemotherapy and radiation therapy. It is not yet known whether Manuka honey is more effective than standard care in preventing pain. PURPOSE: This randomized phase II clinical trial is studying Manuka honey to see how well it works in preventing esophagitis-related pain in patients receiving chemotherapy and radiation therapy for lung cancer.
Checked against the public recordLast updated Aug 31, 2017 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Supportive Care
- Study type
- Interventional
- Phase
- Phase 2
- Sponsor
- Radiation Therapy Oncology Group
- Interventions being studied
- Drug: Manuka honey in liquid form; Drug: Manuka honey in lozenge form; Drug: Standard supportive care
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
DISEASE CHARACTERISTICS: * Patients being treated with combination chemotherapy (definitive or adjuvant) and radiation therapy once daily for small cell or non-small cell lung cancer (primary population for the trial) * Patients can receive chemoradiotherapy while on a Radiation Therapy Oncology Group (RTOG) lung trial or while not being on a clinical trial * No patients receiving chemoradiotherapy while enrolled on a single institution trial or trials coordinated by other cooperative groups * No patients with metastatic disease * At least 5 cm of the esophagus must be in the 60 Gy isodose volume in 1.6 to 2.0 Gy fractions PATIENT CHARACTERISTICS: * Age 18 and up * Able to swallow thick liquids prior to treatment * Able to speak English or Spanish in order to complete required forms (verbal completion is adequate) * No patients with poorly controlled diabetes * No known hypersensitivity to honey PRIOR CONCURRENT THERAPY: * See Disease Characteristics * No patients who have received prior chemotherapy or radiation therapy * No patients receiving more than once daily treatments * Therapeutic use of honey other than the Manuka honey provided for this trial is not allowed while patients are on study * Patients must also avoid honey-flavored medical products and/or sugary, viscous substances * Amifostine is not permitted
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Providence Cancer Center at Providence HospitalMobile, Alabama
- UCSF Helen Diller Family Comprehensive Cancer CenterSan Francisco, California
- Stanford Cancer CenterStanford, California
- CCOP - Christiana Care Health ServicesNewark, Delaware
- Baptist Cancer Institute - JacksonvilleJacksonville, Florida
- CCOP - Mount Sinai Medical CenterMiami Beach, Florida
- Florida Cancer Center - PalatkaPalatka, Florida
- Piedmont Fayette HospitalFayetteville, Georgia
- Nancy N. and J. C. Lewis Cancer and Research Pavilion at St. Joseph's/CandlerSavannah, Georgia
- Queen's Cancer Institute at Queen's Medical CenterHonolulu, Hawaii
- Hawaii Medical Center - EastHonolulu, Hawaii
- OSF St. Francis Medical CenterPeoria, Illinois
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Aug 31, 2017. Always confirm current availability with the study team.